Iconovo and Arcede Pharma take the next step in the development of a new treatment for COPD
Iconovo AB (publ), which develops complete inhalation products for a global market, and Arcede Pharma, which develops inhalation treatments for COPD and…
Iconovo’s partner Monash University has completed enrollment in a Phase I clinical trial of inhaled oxytocin in ICOone
Iconovo announces that the clinical phase I study of oxytocin in the company's inhaler ICOone that was initiated earlier this year in Melbourne, Australia,…
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo has entered into a feasibility…
Iconovo Accelerator Program
On June 1st, 2023 Iconovo launched its Iconovo Accelerator to facilitate the opportunities for the company’s customers to obtain EU funding for the development…
Stora affärsmöjligheter när patent värda 100 miljarder löper ut
Iconovo tillverkar inhalatorer för olika typer av läkemedel. I en bransch där stora läkemedelsbolag dominerar är Iconovo ett av få bolag i världen…
Iconovo är allt närmare vaccin via inhalering
AFFÄRSVÄRLDEN 2023-02-02:
Iconovo är allt närmare vaccin via inhalering, skriver Affärsvärlden idag och rapporterar om extremt lovande resultat…
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se